Chronic migraine treatment: from OnabotulinumtoxinA onwards. (2nd October 2016)

• Record Type: Journal Article
• Authors: Negro, Andrea; Curto, Martina; Lionetto, Luana; Giamberardino, Maria Adele; Martelletti, Paolo
• Is Part Of: Expert review of neurotherapeutics. Volume 16:Number 10(2016)
• Page Start: 1217
• Page End: 1227
• Publication Date: 2016-10-02
• Subjects: migraine -- OnabotulinumtoxinA -- CGRP -- monoclonal antibodies -- migraine prophylaxis; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1080/14737175.2016.1200973
• Languages: English
• ISSNs: 1473-7175

Abstract

ABSTRACT: Introduction : WHO ranks migraine as the 6th highest cause of disability worldwide when considered alone, and the 3rd highest when medication overuse headache (MOH) is included. Migraine is an episodic disorder but in its natural course, its frequency could progressively increase and evolve to a chronic form. More than 50% of chronic migraine patients show acute pain medications overuse which is linked to the development of MOH. Areas covered : Our goal is to review the existing data on OnabotulinoumtoxinA and CGRP-targeting drugs such as anti-CGRP monoclonal antibodies, one of the most promising migraine drugs under development. The research of bibliographic databases has included only published peer-reviewed articles from indexed journals. Expert commentary : To date, real-life studies are supporting OnabotulinumtoxinA in the treatment of chronic migraine. Additionally, anti-CGRP mAbs showed good efficacy and safety in recent RCTs and may soon contribute to improve the quality of life of patients suffering with migraine.